



Clinical trial results:

An open, dose-escalation Phase I/II study to assess the safety, immunogenicity and clinical activity of recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients with PRAME-positive metastatic melanoma

Summary

EudraCT number	2009-016636-13
Trial protocol	DE FR CZ
Global end of trial date	19 December 2016

Results information

Result version number	v2 (current)
This version publication date	11 November 2020
First version publication date	04 January 2018
Version creation reason	<ul style="list-style-type: none">• Correction of full data set Results have been amended to account for consistency with other registries.

Trial information

Trial identification

Sponsor protocol code	113173
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01149343
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	19 June 2017
Is this the analysis of the primary completion data?	Yes
Primary completion date	11 February 2014
Global end of trial reached?	Yes
Global end of trial date	19 December 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

This open-label, Phase I/II study contains two consecutive segments: a dose-escalation Phase I segment and a Phase II segment assessing the clinical activity of the recPRAME + AS15 ASCI at the dose selected.

The co-primary objectives of the Phase I segment of the study were to document and characterize for each dose tested:

- The dose limiting toxicity;
- The anti-PRAME humoral immune response.

The co-primary objectives of the Phase II segment of the study were to characterize:

- The clinical activity of recPRAME + AS15 in terms of objective responses in the overall cohort;
- Any occurrence of dose-limiting toxicity.

Protection of trial subjects:

The patients were observed closely for at least 30 minutes following the administration of the study medication with appropriate medical treatment readily available in case of a rare anaphylactic reaction.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 July 2010
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	1 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Czech Republic: 9
Country: Number of subjects enrolled	Germany: 33
Country: Number of subjects enrolled	France: 14
Country: Number of subjects enrolled	Italy: 30
Country: Number of subjects enrolled	Poland: 6
Country: Number of subjects enrolled	Russian Federation: 14
Worldwide total number of subjects	106
EEA total number of subjects	92

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	55
From 65 to 84 years	50
85 years and over	1

Subject disposition

Recruitment

Recruitment details:

The 106 patients included in the total treated population were enrolled by 31 different study centers.

Pre-assignment

Screening details:

During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

The study is an open-label clinical trial.

Arms

Are arms mutually exclusive?	Yes
Arm title	GSK2302025A Cohort 1

Arm description:

Male or female patients with histologically proven cutaneous melanoma received the investigational Low-Dose (LD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.

Arm type	Experimental
Investigational medicinal product name	Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302025A
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Patients received a total of 24 PRAME ASCI intramuscular administrations, into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection, according to the following schedule: Cycle 1: 6 PRAME ASCI administrations given at 2-week intervals (weeks 0, 2, 4, 6, 8, 10); Cycle 2: 6 PRAME ASCI administrations given at 3-week intervals (weeks 14, 17, 20, 23, 26, 29); Cycle 3: 4 PRAME ASCI administrations given at 6-week intervals (weeks 33, 39, 45, 51); Cycle 4: 4 PRAME ASCI administrations given at 3-month intervals followed by 4 PRAME ASCI administrations given at 6-month intervals.

Arm title	GSK2302025A Cohort 2
-----------	----------------------

Arm description:

Male or female patients with histologically proven cutaneous melanoma received the investigational Middle-Dose (MD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302025A
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Patients received a total of 24 PRAME ASCI intramuscular administrations, into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection, according to the following schedule: Cycle 1: 6 PRAME ASCI administrations given at 2-week intervals (weeks 0, 2, 4, 6, 8, 10); Cycle 2: 6 PRAME ASCI administrations given at 3-week intervals (weeks 14, 17, 20, 23, 26, 29); Cycle 3: 4 PRAME ASCI administrations given at 6-week intervals (weeks 33, 39, 45, 51); Cycle 4: 4 PRAME ASCI administrations given at 3-month intervals followed by 4 PRAME ASCI administrations given at 6-month intervals.

Arm title	GSK2302025A Cohort 3
------------------	----------------------

Arm description:

Male or female patients with histologically proven cutaneous melanoma received the investigational High-Dose (HD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.

Arm type	Experimental
Investigational medicinal product name	Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302025A
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Patients received a total of 24 PRAME ASCI intramuscular administrations, into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection, according to the following schedule: Cycle 1: 6 PRAME ASCI administrations given at 2-week intervals (weeks 0, 2, 4, 6, 8, 10); Cycle 2: 6 PRAME ASCI administrations given at 3-week intervals (weeks 14, 17, 20, 23, 26, 29); Cycle 3: 4 PRAME ASCI administrations given at 6-week intervals (weeks 33, 39, 45, 51); Cycle 4: 4 PRAME ASCI administrations given at 3-month intervals followed by 4 PRAME ASCI administrations given at 6-month intervals.

Arm title	GSK2302025A Cohort 4
------------------	----------------------

Arm description:

In Phase 2 of the study subjects received the optimal investigational dose-level identified in Phase 1. Patients received a treatment consisting of 24 injections of the experimental GSK2302025A immunotherapeutic.

Arm type	Experimental
Investigational medicinal product name	Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302025A
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Patients received a total of 24 PRAME ASCI intramuscular administrations, into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection, according to the following schedule: Cycle 1: 6 PRAME ASCI administrations given at 2-week intervals (weeks 0, 2, 4, 6, 8, 10); Cycle 2: 6 PRAME ASCI administrations given at 3-week intervals (weeks 14, 17, 20, 23, 26, 29); Cycle 3: 4 PRAME ASCI administrations given at 6-week intervals (weeks 33, 39, 45, 51); Cycle 4: 4 PRAME ASCI administrations given at 3-month intervals followed by 4 PRAME ASCI administrations given at 6-month intervals.

Number of subjects in period 1	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3
Started	20	24	22
Completed	0	0	0
Not completed	20	24	22
Adverse event, serious fatal	10	13	18
Consent withdrawn by subject	1	1	1
Recurrence / Progressive disease	-	-	1
Sponsor study termination	-	-	-
Unspecified	8	10	2
Lost to follow-up	1	-	-

Number of subjects in period 1	GSK2302025A Cohort 4
Started	40
Completed	0
Not completed	40
Adverse event, serious fatal	18
Consent withdrawn by subject	5
Recurrence / Progressive disease	-
Sponsor study termination	2
Unspecified	14
Lost to follow-up	1

Baseline characteristics

Reporting groups

Reporting group title	GSK2302025A Cohort 1
Reporting group description:	
Male or female patients with histologically proven cutaneous melanoma received the investigational Low-Dose (LD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.	
Reporting group title	GSK2302025A Cohort 2
Reporting group description:	
Male or female patients with histologically proven cutaneous melanoma received the investigational Middle-Dose (MD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.	
Reporting group title	GSK2302025A Cohort 3
Reporting group description:	
Male or female patients with histologically proven cutaneous melanoma received the investigational High-Dose (HD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.	
Reporting group title	GSK2302025A Cohort 4
Reporting group description:	
In Phase 2 of the study subjects received the optimal investigational dose-level identified in Phase 1. Patients received a treatment consisting of 24 injections of the experimental GSK2302025A immunotherapeutic.	

Reporting group values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3
Number of subjects	20	24	22
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	60.3	60.8	59.5
standard deviation	± 14.9	± 15.5	± 15.2
Gender categorical			
Units: Subjects			
Female	7	11	10
Male	13	13	12
Race/Ethnicity, Customized			
Units: Subjects			
White - Caucasian / European Heritage	20	23	21
Other	0	1	1

Reporting group values	GSK2302025A	Total	
------------------------	-------------	-------	--

Cohort 4

Number of subjects	40	106	
Age categorical			
Units: Subjects			
Age continuous			
Units: years			
arithmetic mean	60.7		
standard deviation	± 18.1	-	
Gender categorical			
Units: Subjects			
Female	29	57	
Male	11	49	
Race/Ethnicity, Customized			
Units: Subjects			
White - Caucasian / European	40	104	
Heritage			
Other	0	2	

End points

End points reporting groups

Reporting group title	GSK2302025A Cohort 1
Reporting group description: Male or female patients with histologically proven cutaneous melanoma received the investigational Low-Dose (LD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.	
Reporting group title	GSK2302025A Cohort 2
Reporting group description: Male or female patients with histologically proven cutaneous melanoma received the investigational Middle-Dose (MD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.	
Reporting group title	GSK2302025A Cohort 3
Reporting group description: Male or female patients with histologically proven cutaneous melanoma received the investigational High-Dose (HD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.	
Reporting group title	GSK2302025A Cohort 4
Reporting group description: In Phase 2 of the study subjects received the optimal investigational dose-level identified in Phase 1. Patients received a treatment consisting of 24 injections of the experimental GSK2302025A immunotherapeutic.	

Primary: Number of patients with dose-limiting toxicity (Phase I)

End point title	Number of patients with dose-limiting toxicity (Phase I) ^{[1][2]}
End point description: The dose-limiting toxicities (DLT) were defined as follows: •An Antigen-Specific Cancer Immunotherapeutic (ASCI) related or possibly ASCI related grade 3 or higher toxicity. Grade 3 myalgia, arthralgia, headache, fever, rigors/chills and fatigue (including lethargy, malaise and asthenia) persisting for 48 hours despite therapy. •An ASCI related or possibly ASCI related grade 2 or higher allergic reaction occurring within 24 hours following the ASCI administration. •An ASCI related or possibly ASCI related decrease in renal function, with a creatinine clearance lower than (<) 40 milliliters per minute (mL/min). •An ASCI-related or possibly ASCI-related symptomatic and confirmed adrenal insufficiency. The grading used was defined according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0: Grade 3 DLT = severe DLT. Related = DLT considered by investigator as possibly related to product administration.	
End point type	Primary
End point timeframe: During the study treatment (up to 4 years), for all patients	
Notes:	

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The scope of this primary end point was descriptive, no statistical hypothesis test was performed.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each

related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	20	24	22	
Units: Days				
Patients with DLT	0	1	1	
Patients with related DLT	0	1	1	
Patients with severe DLT	0	1	1	
Brain oedema	0	1	0	
Microalbuminuria	0	0	1	
Proteinuria	0	0	1	

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of patients with anti-PReferentially expressed Antigen of MELanoma (Anti-PRAME) humoral immune response (Phase I)

End point title	Percentage of patients with anti-PReferentially expressed Antigen of MELanoma (Anti-PRAME) humoral immune response (Phase I) ^{[3][4]}
-----------------	------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

A seronegative/seropositive patient for anti-PRAME antibodies was a patient with antibody concentration lower (<)/ higher than or equal to (≥) cut-off level. Humoral immune response was defined as a) if baseline concentration < cut-off level: post treatment concentration ≥ cut-off level, or b) if baseline concentration ≥ cut-off level: post treatment concentration at least twice the baseline value. Cut-off values for seropositivity (by enzyme-linked immunosorbent assay [ELISA]) were 12 ELISA Units per milliliter (EL.U/mL).

End point type	Primary
----------------	---------

End point timeframe:

After the administration of dose 4 at Week 8

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The scope of this primary end point was descriptive, no statistical hypothesis test was performed.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	13	13	17	
Units: Percentage of patients				
number (confidence interval 95%)				
Percentage of patients	100 (75.3 to 100)	100 (75.3 to 100)	100 (80.5 to 100)	

Statistical analyses

No statistical analyses for this end point

Primary: Number of patients with best overall response to study treatment (Phase II)

End point title	Number of patients with best overall response to study treatment (Phase II) ^[5]
-----------------	--------------------------------------------------------------------------------------------

End point description:

The best overall response is the best response recorded from the start of the treatment until disease progression (taking as reference for progressive disease the smallest measurements recorded since the treatment started). In general the patient's best response assignment depended on the achievement of both measurement and confirmation criteria. The best overall response includes the complete response (CR) defined as disappearance of all targeted/non-targeted lesions and partial response (PR) defined as at least 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference the baseline sum LD and persistence of one or more non-targeted lesion(s).

End point type	Primary
----------------	---------

End point timeframe:

Up to study conclusion at year 4 + 1 month

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The scope of this primary end point was descriptive, no statistical hypothesis test was performed.

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	GSK2302025A Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	24	22	40
Units: Participants				
CR	0	0	0	0
PR	0	0	0	4

Statistical analyses

No statistical analyses for this end point

Secondary: Number of patients with any unsolicited adverse events (AEs), by maximum grading

End point title	Number of patients with any unsolicited adverse events (AEs), by maximum grading
-----------------	----------------------------------------------------------------------------------

End point description:

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. The grading to be used by the investigators for the assessment of the severity of adverse events (AEs) was defined as

End point type	Secondary
End point timeframe:	
During the study treatment period until 30 days after the last administration	

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	GSK2302025A Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	24	22	40
Units: Participants				
Grade 1	9	9	8	12
Grade 2	6	6	10	15
Grade 3	4	5	3	7
Grade 4	1	1	0	3
Grade 5	0	0	0	2

Statistical analyses

No statistical analyses for this end point

Secondary: Number of patients with Serious Adverse Events (SAEs), by maximum grading

End point title	Number of patients with Serious Adverse Events (SAEs), by maximum grading
End point description:	
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. The grading to be used by the investigators for the assessment of the severity of adverse events (AEs) was defined as the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0.	
End point type	Secondary
End point timeframe:	
During the study period - up to 4 years + 1 month post last study treatment administration	

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	GSK2302025A Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	24	22	40
Units: Participants				
Grade 1	0	0	0	0
Grade 2	0	0	1	0
Grade 3	2	2	1	0
Grade 4	1	1	0	3
Grade 5	0	0	0	2

Statistical analyses

No statistical analyses for this end point

Secondary: Number of patients with laboratory abnormalities versus baseline, by maximum grading

End point title	Number of patients with laboratory abnormalities versus baseline, by maximum grading
End point description:	
Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged [APTTP], alanine aminotransferase increased [ALT/I], alkaline phosphatase increased [APH/I], anemia [AN], aspartate aminotransferase increased [AST/I], blood bilirubin increased [BB/I], creatinine increased [CRE/I], gamma glutamyltransferase increased [GGT/I], hemoglobin increased [Hgb/I], hypoalbuminemia [HYP], lymphocyte count decreased [LYMC/D], lymphocyte count increased [LYMC/I], neutrophil count decreased [NEUC/D], platelet count decreased [PLA/D], white blood cell decreased [WBC/D]. Parameter grades (G0,1,2,3,4,Unknown) were compared to baseline parameter grades (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 [http://evs.nci.nih.gov/ftp1/CTCAE]. This endpoint presents values for [APTTP] grading versus baseline parameter grading.	
End point type	Secondary
End point timeframe:	
During the study period - up to 4 years + 1 month post last study treatment administration	

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	GSK2302025A Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	24	22	40
Units: Participants				
[APTTP], G0-GUnknown	0	0	0	0
[APTTP], G1-GUnknown	0	0	0	0
[APTTP], G2-GUnknown	0	0	0	0
[APTTP], G3-GUnknown	0	0	0	1
[APTTP], G4-GUnknown	0	0	0	0
[APTTP], GUnknown-GUnknown	2	0	1	0
[APTTP], G0-G0	13	16	18	33
[APTTP], G1-G0	2	3	1	3
[APTTP], G2-G0	0	0	1	0
[APTTP], G3-G0	0	1	0	1
[APTTP], G4-G0	0	0	0	0
[APTTP], GUnknown-G0	2	0	1	0
[APTTP], G0-G1	0	1	0	1
[APTTP], G1-G1	0	2	0	0
[APTTP], G2-G1	0	0	0	1
[APTTP], G3-G1	0	0	0	0
[APTTP], G4-G1	0	0	0	0
[APTTP], GUnknown-G1	0	1	0	0

[APTTP], G0-G2	0	0	0	0
[APTTP], G1-G2	0	0	0	0
[APTTP], G2-G2	1	0	0	0
[APTTP], G3-G2	0	0	0	0
[APTTP], G4-G2	0	0	0	0
[APTTP], GUnknown-G2	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Secondary: Number of patients with laboratory abnormalities versus baseline, by maximum grading

End point title	Number of patients with laboratory abnormalities versus baseline, by maximum grading
-----------------	--------------------------------------------------------------------------------------

End point description:

Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged [APTTP], alanine aminotransferase increased [ALT/I], alkaline phosphatase increased [APH/I], anemia [AN], aspartate aminotransferase increased [AST/I], blood bilirubin increased [BB/I], creatinine increased [CRE/I], gamma glutamyltransferase increased [GGT/I], hemoglobin increased [Hgb/I], hypoalbuminemia [HYP], lymphocyte count decreased [LYMC/D], lymphocyte count increased [LYMC/I], neutrophil count decreased [NEUC/D], platelet count decreased [PLA/D], white blood cell decreased [WBC/D]. Parameter grades (G0,1,2,3,4,Unknown) were compared to baseline parameter grades (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 [<http://evs.nci.nih.gov/ftp1/CTCAE>]. This endpoint presents values for [ALT/I] and [APH/I] grading versus baseline parameter grading.

End point type	Secondary
----------------	-----------

End point timeframe:

During the study period - up to 4 years + 1 month post last study treatment administration

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	GSK2302025A Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	24	22	40
Units: Participants				
[ALT/I], G0-G0	11	18	16	34
[ALT/I], G1-G0	4	4	5	1
[ALT/I], G2-G0	0	0	0	1
[ALT/I], G3-G0	0	0	0	0
[ALT/I], G4-G0	0	0	0	0
[ALT/I], GUnknown-G0	2	0	1	0
[ALT/I], G0-G1	0	2	0	1
[ALT/I], G1-G1	3	0	0	3
[ALT/I], G2-G1	0	0	0	0
[ALT/I], G3-G1	0	0	0	0
[ALT/I], G4-G1	0	0	0	0
[ALT/I], GUnknown-G1	0	0	0	0
[APH/I], G0-G0	16	20	15	33
[APH/I], G1-G0	1	3	5	5
[APH/I], G2-G0	0	0	1	1

[APH/I], G3-G0	0	0	0	0
[APH/I], G4-G0	0	0	0	0
[APH/I], GUknown-G0	2	0	1	0
[APH/I], G0-G1	0	0	0	0
[APH/I], G1-G1	0	0	0	1
[APH/I], G2-G1	0	1	0	0
[APH/I], G3-G1	0	0	0	0
[APH/I], G4-G1	0	0	0	0
[APH/I], GUknown-G1	0	0	0	0
[APH/I], G0-G2	0	0	0	0
[APH/I], G1-G2	0	0	0	0
[APH/I], G2-G2	0	0	0	0
[APH/I], G3-G2	1	0	0	0
[APH/I], G4-G2	0	0	0	0
[APH/I], GUknown-G2	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Secondary: Number of patients with hematological and biochemical abnormalities versus baseline, by maximum grading

End point title	Number of patients with hematological and biochemical abnormalities versus baseline, by maximum grading
-----------------	---------------------------------------------------------------------------------------------------------

End point description:

Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged [APTT], alanine aminotransferase increased [ALT/I], alkaline phosphatase increased [APH/I], anemia [AN], aspartate aminotransferase increased [AST/I], blood bilirubin increased [BB/I], creatinine increased [CRE/I], gamma glutamyltransferase increased [GGT/I], hemoglobin increased [Hgb/I], hypoalbuminemia [HYP], lymphocyte count decreased [LYMC/D], lymphocyte count increased [LYMC/I], neutrophil count decreased [NEUC/D], platelet count decreased [PLA/D], white blood cell decreased [WBC/D]. Parameter grades (G0,1,2,3,4,Uknown) were compared to baseline parameter grades (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 [<http://evs.nci.nih.gov/ftp1/CTCAE>]. This endpoint presents values for [AN], [AST/I] and [CRE/I] grading versus baseline parameter grading.

End point type	Secondary
----------------	-----------

End point timeframe:

During the study period - up to 4 years + 1 month post last study treatment administration

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	GSK2302025A Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	24	22	40
Units: Participants				
[AN], G0-G0	12	10	10	21
[AN], G1-G0	1	6	5	12
[AN], G2-G0	0	0	1	3
[AN], G3-G0	1	0	0	0
[AN], G4-G0	0	0	0	0
[AN], GUknown-G0	1	0	1	0

[AN], G0-G1	2	1	0	0
[AN], G1-G1	2	5	5	4
[AN], G2-G1	0	1	0	0
[AN], G3-G1	0	1	0	0
[AN], G4-G1	0	0	0	0
[AN], GUnknown-G1	1	0	0	0
[AST/I], G0-G0	13	18	17	36
[AST/I], G1-G0	3	6	4	2
[AST/I], G2-G0	0	0	0	0
[AST/I], G3-G0	0	0	0	0
[AST/I], G4-G0	0	0	0	0
[AST/I], GUnknown-G0	1	0	1	0
[AST/I], G0-G1	1	0	0	0
[AST/I], G1-G1	1	0	0	2
[AST/I], G2-G1	0	0	0	0
[AST/I], G3-G1	0	0	0	0
[AST/I], G4-G1	0	0	0	0
[AST/I], GUnknown-G1	1	0	0	0
[BB/I], G0-G0	16	21	19	38
[BB/I], G1-G0	1	2	1	0
[BB/I], G2-G0	1	0	0	0
[BB/I], G3-G0	0	0	0	0
[BB/I], G4-G0	0	0	0	0
[BB/I], GUnknown-G0	2	0	1	0
[BB/I], G0-G1	0	0	0	0
[BB/I], G1-G1	0	1	1	1
[BB/I], G2-G1	0	0	0	1
[BB/I], G3-G1	0	0	0	0
[BB/I], G4-G1	0	0	0	0
[BB/I], GUnknown-G1	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Secondary: Number of patients with laboratory hematological and biochemical abnormalities versus baseline, by maximum grading

End point title	Number of patients with laboratory hematological and biochemical abnormalities versus baseline, by maximum grading
-----------------	--------------------------------------------------------------------------------------------------------------------

End point description:

Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged [APTT], alanine aminotransferase increased [ALT/I], alkaline phosphatase increased [APH/I], anemia [AN], aspartate aminotransferase increased [AST/I], blood bilirubin increased [BB/I], creatinine increased [CRE/I], gamma glutamyltransferase increased [GGT/I], hemoglobin increased [Hgb/I], hypoalbuminemia [HYP], lymphocyte count decreased [LYMC/D], lymphocyte count increased [LYMC/I], neutrophil count decreased [NEUC/D], platelet count decreased [PLA/D], white blood cell decreased [WBC/D]. Parameter grades (G0,1,2,3,4,Unknown) were compared to baseline parameter grades (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 [<http://evs.nci.nih.gov/ftp1/CTCAE>]. This endpoint presents values for [CRE/I] and [GGT/I] grading versus baseline parameter grading.

End point type	Secondary
----------------	-----------

End point timeframe:

During the study period - up to 4 years + 1 month post last study treatment administration

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	GSK2302025A Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	24	22	40
Units: Participants				
[CRE/I], G0-G0	20	22	20	33
[CRE/I], G1-G0	0	0	1	6
[CRE/I], G2-G0	0	0	0	0
[CRE/I], G3-G0	0	0	0	0
[CRE/I], G4-G0	0	0	0	0
[CRE/I], GUnknown-G0	0	0	0	0
[CRE/I], G0-G1	0	0	0	0
[CRE/I], G1-G1	0	1	1	0
[CRE/I], G2-G1	0	0	0	0
[CRE/I], G3-G1	0	0	0	0
[CRE/I], G4-G1	0	0	0	0
[CRE/I], GUnknown-G1	0	0	0	0
[CRE/I], G0-G2	0	0	0	0
[CRE/I], G1-G2	0	0	0	0
[CRE/I], G2-G2	0	1	0	1
[CRE/I], G3-G2	0	0	0	0
[CRE/I], G4-G2	0	0	0	0
[CRE/I], GUnknown-G2	0	0	0	0
[GGT/I], G0-G0	10	17	14	30
[GGT/I], G1-G0	1	1	1	4
[GGT/I], G2-G0	2	2	1	0
[GGT/I], G3-G0	0	0	0	0
[GGT/I], G4-G0	0	0	0	1
[GGT/I], GUnknown-G0	1	0	1	0
[GGT/I], G0-G1	2	1	1	1
[GGT/I], G1-G1	0	1	1	3
[GGT/I], G2-G1	1	1	0	0
[GGT/I], G3-G1	0	0	1	0
[GGT/I], G4-G1	0	0	0	0
[GGT/I], GUnknown-G1	1	0	0	0
[GGT/I], G0-G2	0	0	0	0
[GGT/I], G1-G2	0	1	0	0
[GGT/I], G2-G2	0	0	0	0
[GGT/I], G3-G2	1	0	2	0
[GGT/I], G4-G2	0	0	0	0
[GGT/I], GUnknown-G2	1	0	0	0
[GGT/I], G0-G3	0	0	0	0
[GGT/I], G1-G3	0	0	0	0
[GGT/I], G2-G3	0	0	0	0
[GGT/I], G3-G3	0	0	0	1
[GGT/I], G4-G3	0	0	0	0

[GGT/I], GUnknown-G3	0	0	0	0
----------------------	---	---	---	---

Statistical analyses

No statistical analyses for this end point

Secondary: Number of patients with laboratory hematological and biochemical abnormalities versus baseline, by maximum grading

End point title	Number of patients with laboratory hematological and biochemical abnormalities versus baseline, by maximum grading
End point description:	
Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged [APTT], alanine aminotransferase increased [ALT/I], alkaline phosphatase increased [APH/I], anemia [AN], aspartate aminotransferase increased [AST/I], blood bilirubin increased [BB/I], creatinine increased [CRE/I], gamma glutamyltransferase increased [GGT/I], hemoglobin increased [Hgb/I], hypoalbuminemia [HYP], lymphocyte count decreased [LYMC/D], lymphocyte count increased [LYMC/I], neutrophil count decreased [NEUC/D], platelet count decreased [PLA/D], white blood cell decreased [WBC/D]. Parameter grades (G0,1,2,3,4,Uknown) were compared to baseline parameter grades (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 [http://evs.nci.nih.gov/ftp1/CTCAE]. This endpoint presents values for [Hgb/I] and [HYP] grading versus baseline parameter grading.	
End point type	Secondary
End point timeframe:	
During the study period - up to 4 years + 1 month post last study treatment administration	

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	GSK2302025A Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	24	22	40
Units: Participants				
[Hgb/I], G0-G0	16	24	21	37
[Hgb/I], G1-G0	0	0	0	2
[Hgb/I], G2-G0	0	0	0	0
[Hgb/I], G3-G0	0	0	0	0
[Hgb/I], G4-G0	0	0	0	0
[Hgb/I], GUnknown-G0	2	0	1	0
[Hgb/I], G0-G1	0	0	0	0
[Hgb/I], G1-G1	1	0	0	0
[Hgb/I], G2-G1	0	0	0	1
[Hgb/I], G3-G1	0	0	0	0
[Hgb/I], G4-G1	0	0	0	0
[Hgb/I], GUnknown-G1	0	0	0	0
[Hgb/I], G0-G2	0	0	0	0
[Hgb/I], G1-G2	1	0	0	0
[Hgb/I], G2-G2	0	0	0	0
[Hgb/I], G3-G2	0	0	0	0
[Hgb/I], G4-G2	0	0	0	0

[Hgb/I], GUnknown-G2	0	0	0	0
[HYP], G0-G0	13	17	18	30
[HYP], G1-G0	2	5	2	5
[HYP], G2-G0	0	1	0	1
[HYP], G3-G0	0	0	0	0
[HYP], G4-G0	0	0	0	0
[HYP], GUnknown-G0	3	0	2	0
[HYP], G0-G1	0	0	0	0
[HYP], G1-G1	1	1	0	3
[HYP], G2-G1	1	0	0	0
[HYP], G3-G1	0	0	0	0
[HYP], G4-G1	0	0	0	0
[HYP], GUnknown-G1	0	0	0	0
[HYP], G0-G3	0	0	0	1
[HYP], G1-G3	0	0	0	0
[HYP], G2-G3	0	0	0	0
[HYP], G3-G3	0	0	0	0
[HYP], G4-G3	0	0	0	0
[HYP], GUnknown-G3	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Secondary: Number of patients with abnormal hematological and biochemical results versus baseline, by maximum grading

End point title	Number of patients with abnormal hematological and biochemical results versus baseline, by maximum grading
-----------------	------------------------------------------------------------------------------------------------------------

End point description:

Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged [APTT], alanine aminotransferase increased [ALT/I], alkaline phosphatase increased [APH/I], anemia [AN], aspartate aminotransferase increased [AST/I], blood bilirubin increased [BB/I], creatinine increased [CRE/I], gamma glutamyltransferase increased [GGT/I], hemoglobin increased [Hgb/I], hypoalbuminemia [HYP], lymphocyte count decreased [LYMC/D], lymphocyte count increased [LYMC/I], neutrophil count decreased [NEUC/D], platelet count decreased [PLA/D], white blood cell decreased [WBC/D]. Parameter grades (G0,1,2,3,4,Unknown) were compared to baseline parameter grades (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 [<http://evs.nci.nih.gov/ftp1/CTCAE>]. This endpoint presents values for [LYMC/D] and [LYMC/I] grading versus baseline parameter grading.

End point type	Secondary
----------------	-----------

End point timeframe:

During the study period - up to 4 years + 1 month post last study treatment administration

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	GSK2302025A Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	24	22	40
Units: Participants				
[LYMC/D], G0-G0	10	14	14	28
[LYMC/D], G1-G0	3	4	3	4

[LYMC/D], G2-G0	1	1	0	0
[LYMC/D], G3-G0	0	0	0	0
[LYMC/D], G4-G0	0	0	0	0
[LYMC/D], GUnknown-G0	0	0	1	0
[LYMC/D], G0-G1	0	1	1	2
[LYMC/D], G1-G1	3	3	2	5
[LYMC/D], G2-G1	1	0	0	0
[LYMC/D], G3-G1	0	0	0	0
[LYMC/D], G4-G1	0	0	0	0
[LYMC/D], GUnknown-G1	1	1	0	0
[LYMC/D], G0-G2	0	0	0	0
[LYMC/D], G1-G2	0	0	1	0
[LYMC/D], G2-G2	0	0	0	1
[LYMC/D], G3-G2	0	0	0	0
[LYMC/D], G4-G2	0	0	0	0
[LYMC/D], GUnknown-G2	0	0	0	0
[LYMC/D], G0-G3	0	0	0	0
[LYMC/D], G1-G3	0	0	0	0
[LYMC/D], G2-G3	0	0	0	0
[LYMC/D], G3-G3	0	0	0	0
[LYMC/D], G4-G3	0	0	0	0
[LYMC/D], GUnknown-G3	1	0	0	0
[LYMC/I], G0-G0	16	23	21	40
[LYMC/I], G1-G0	0	0	0	0
[LYMC/I], G2-G0	2	0	0	0
[LYMC/I], G3-G0	0	0	0	0
[LYMC/I], G4-G0	0	0	0	0
[LYMC/I], GUnknown-G0	2	1	1	0

Statistical analyses

No statistical analyses for this end point

Secondary: Number of patients with abnormal hematological and biochemical results versus baseline, by maximum grading

End point title	Number of patients with abnormal hematological and biochemical results versus baseline, by maximum grading
-----------------	------------------------------------------------------------------------------------------------------------

End point description:

Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged [APTT], alanine aminotransferase increased [ALT/I], alkaline phosphatase increased [APH/I], anemia [AN], aspartate aminotransferase increased [AST/I], blood bilirubin increased [BB/I], creatinine increased [CRE/I], gamma glutamyltransferase increased [GGT/I], hemoglobin increased [Hgb/I], hypoalbuminemia [HYP], lymphocyte count decreased [LYMC/D], lymphocyte count increased [LYMC/I], neutrophil count decreased [NEUC/D], platelet count decreased [PLA/D], white blood cell decreased [WBC/D]. Parameter grades (G0,1,2,3,4,Unknown) were compared to baseline parameter grades (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 [<http://evs.nci.nih.gov/ftp1/CTCAE>]. This endpoint presents values for [NEUC/D], [PLA/D] and [WBC/D] grading versus baseline parameter grading.

End point type	Secondary
----------------	-----------

End point timeframe:

During the study period - up to 4 years + 1 month post last study treatment administration

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	GSK2302025A Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	24	22	40
Units: Participants				
[NEUC/D], G0-G0	17	21	21	39
[NEUC/D], G1-G0	1	2	0	0
[NEUC/D], G2-G0	0	0	0	0
[NEUC/D], G3-G0	0	0	0	0
[NEUC/D], G4-G0	0	0	0	0
[NEUC/D], GUnknown-G0	2	1	1	0
[NEUC/D], G0-G1	0	0	0	0
[NEUC/D], G1-G1	0	0	0	1
[NEUC/D], G2-G1	0	0	0	0
[NEUC/D], G3-G1	0	0	0	0
[NEUC/D], G4-G1	0	0	0	0
[NEUC/D], GUnknown-G1	0	0	0	0
[PLA/D], G0-G0	17	24	20	38
[PLA/D], G1-G0	1	0	0	2
[PLA/D], G2-G0	0	0	0	0
[PLA/D], G3-G0	0	0	0	0
[PLA/D], G4-G0	0	0	0	0
[PLA/D], GUnknown-G0	2	0	1	0
[PLA/D], G0-G1	0	0	0	0
[PLA/D], G1-G1	0	0	1	0
[PLA/D], G2-G1	0	0	0	0
[PLA/D], G3-G1	0	0	0	0
[PLA/D], G4-G1	0	0	0	0
[PLA/D], GUnknown-G1	0	0	0	0
[WBC/D], G0-G0	14	21	19	34
[WBC/D], G1-G0	2	1	1	3
[WBC/D], G2-G0	0	0	0	0
[WBC/D], G3-G0	0	0	0	0
[WBC/D], G4-G0	0	0	0	0
[WBC/D], GUnknown-G0	2	0	1	0
[WBC/D], G0-G1	1	0	0	2
[WBC/D], G1-G1	1	2	1	1
[WBC/D], G2-G1	0	0	0	0
[WBC/D], G3-G1	0	0	0	0
[WBC/D], G4-G1	0	0	0	0
[WBC/D], GUnknown-G1	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of patients with anti-PRAME cellular (T-cell) response (Phase I)

End point title	Percentage of patients with anti-PRAME cellular (T-cell) response (Phase I) ^[6]
-----------------	--------------------------------------------------------------------------------------------

End point description:

Cellular response was defined as: Geometric Mean Response (GMR) above the 2.68 cut-off value and at least a four-fold increase of PRAME- specific Cluster of Differentiation (CD) 4/8 T cells. Considering that 2 studies failed to demonstrate clinical efficacy of recombinant protein based cancer vaccines, GSK decided in 2014 to stop the development and to stop recruitment in all the ongoing clinical studies. The decision was made to end the study (i.e., stopping patient enrollment, follow-ups, sample collection and analysis of samples for research purposes). Patients still on treatment at the time of the protocol amendment were offered to continue the administration of the study treatment until the last dose or until recurrence, whichever came first, or until the patient or the investigator decided to stop the study treatment. No further active protocol visit/contact was performed except for the concluding visit 30 days after the last treatment administration.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Data Lock Point at Week 8

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	8	11	14	
Units: Percentage of patients				
number (confidence interval 95%)				
Patients with pre+post-administration results CD4	100 (63.1 to 100)	100 (71.5 to 100)	100 (76.8 to 100)	
Responders CD4	75.0 (34.9 to 96.8)	45.5 (16.7 to 76.6)	57.1 (28.9 to 82.3)	
Patients with pre+post-administration results CD8	100 (63.1 to 100)	100 (66.4 to 100)	100 (63.1 to 100)	
Responders CD8	0.0 (0.0 to 36.9)	0.0 (0.0 to 33.6)	0.0 (0.0 to 36.9)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with anti-PRAME humoral immune response (Phase I & II)

End point title	Number of subjects with anti-PRAME humoral immune response (Phase I & II)
-----------------	---------------------------------------------------------------------------

End point description:

A seropositive subject is a subject whose antibody concentrations are greater than or equal to the assay cut-off value of 12 EL/mL.

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 0, 4, 8, 10, 12, 29, 51, 75, 99 123, 147 and conclusion visit at 30 days post last treatment administration for each patient

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	GSK2302025A Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	24	22	40
Units: Participants				
anti-PRAME, week 0	0	0	0	2
anti-PRAME, week 4	11	14	18	33
anti-PRAME, week 8	14	13	21	33
anti-PRAME, week 10	10	12	19	33
anti-PRAME, week 12	9	9	16	28
anti-PRAME, week 29	2	4	5	13
anti-PRAME, week 51	1	3	3	7
anti-PRAME, week 75	2	2	2	1
anti-PRAME, week 99	2	2	2	0
anti-PRAME, week 123	1	1	1	0
anti-PRAME, week 147	1	0	0	0
anti-PRAME, conclusion visit	6	12	8	23

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with best overall response, including Mixed Response (MxR) and Slow Progressive Disease (SPD) criteria (Phase I & II)

End point title	Number of subjects with best overall response, including Mixed Response (MxR) and Slow Progressive Disease (SPD) criteria (Phase I & II)
-----------------	------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Tumor response was assessed by the RECIST criteria, where SD for target lesions refers to neither enough shrinkage to qualify for CR nor sufficient increase to qualify for PD taking as references the smallest sum LD since the treatment started. For non-targeted lesions it refers to persistence of one or more non-target lesions. Progressive disease is related to a clear increase of diameters of lesions taking as references the smallest diameters recorded since the treatment started OR the appearance of one or more new lesions OR both of these. Mixed response is defined as at least 30% decrease in the longest diameter (LD) occurring in at least one target lesion recorded and measured at baseline. Such response occurring in otherwise SD or PD status of the LD of target lesions were classified as "SD with target lesion regression" or "PD with target lesion regression", respectively. New lesion(s) in otherwise PR status of the LD of target lesions were "PR with new lesion".

End point type	Secondary
----------------	-----------

End point timeframe:

At 30 days after the last treatment administration for each patient

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	GSK2302025A Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	24	22	40
Units: Participants				
PR	0	0	0	0
CR	0	0	0	4
MxR: SD with target lesion regression	0	0	0	0
MxR: PD with target lesion regression	2	2	2	3
MxR: PR with new lesion	0	0	1	0
SD/PR	0	1	1	3
SD without mixed response	2	0	1	1
PD with SPD criteria	3	5	4	19
PD without SPD/MxR	4	12	8	9
Non Evaluable	2	1	0	1
Missing Best overall response	7	3	5	0

Statistical analyses

No statistical analyses for this end point

Secondary: The anti-Protein D humoral response (Phase I)

End point title	The anti-Protein D humoral response (Phase I)
-----------------	-----------------------------------------------

End point description:

Analysis of immunogenicity for anti-PD antibodies was not performed, following negative results to the NCT00480025 study which assessed another study product from same technology platform. For this study, the main analysis of the dose-escalation Phase I segment was performed according to protocol when all patients enrolled in the Phase I segment had received the first 4 treatment doses and had completed Week 8. The main analysis of the Phase II segment was performed according to protocol when all patients had either completed the treatment until the end of Cycle 3 or had been withdrawn from the study treatment, with the exception of anti-PD antibody responses and PRAME-specific cellular responses which were not yet performed. All samples that had been collected but not yet tested were not tested by default, except if a scientific rationale remained relevant.

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 0, 4, 8, 12, 29, 51, 75, 99, 123, 147, 30 days after the last treatment administration for each patient, with follow-up, 3, 6, 9 and 12 months after concluding visit

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	GSK2302025A Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[7]	0 ^[8]	0 ^[9]	0 ^[10]
Units: Titer				
geometric mean (confidence interval 95%)				
Titer	(to)	(to)	(to)	(to)

Notes:

[7] - Analysis of immunogenicity for anti-PD antibodies was not performed.

[8] - Analysis of immunogenicity for anti-PD antibodies was not performed.

[9] - Analysis of immunogenicity for anti-PD antibodies was not performed.

[10] - Analysis of immunogenicity for anti-PD antibodies was not performed.

Statistical analyses

No statistical analyses for this end point

Secondary: The anti-Cytosine Phosphate Guanosine oligodeoxynucleotide (CpG) humoral response (Phase I & II)

End point title	The anti-Cytosine Phosphate Guanosine oligodeoxynucleotide (CpG) humoral response (Phase I & II)
-----------------	--------------------------------------------------------------------------------------------------

End point description:

Analysis of immunogenicity for anti-CpG antibodies was not performed, following negative results to the NCT00480025 study which assessed another study product from same technology platform. For this study, the main analysis of the dose-escalation Phase I segment was performed according to protocol when all patients enrolled in the Phase I segment had received the first 4 treatment doses and had completed Week 8. The main analysis of the Phase II segment was performed according to protocol when all patients had either completed the treatment until the end of Cycle 3 or had been withdrawn from the study treatment, with the exception of anti-CpG antibody responses and PRAME-specific cellular responses which were not yet performed. All samples that had been collected but not yet tested were not tested by default, except if a scientific rationale remained relevant.

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 0, 4, 8, 12, 29, 51, years 1.5, 2, 2.5, 3, 3.5, 4 years + 1 month, with follow-up, 3, 6, 9 and 12 months after concluding visit

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	GSK2302025A Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[11]	0 ^[12]	0 ^[13]	0 ^[14]
Units: Specific T-cells/million T-cells				
arithmetic mean (standard deviation)				
Specific T-cells/million T-cells	()	()	()	()

Notes:

[11] - Analysis of immunogenicity for anti-CpG antibodies was not performed.

[12] - Analysis of immunogenicity for anti-CpG antibodies was not performed.

[13] - Analysis of immunogenicity for anti-CpG antibodies was not performed.

[14] - Analysis of immunogenicity for anti-CpG antibodies was not performed.

Statistical analyses

No statistical analyses for this end point

Secondary: Time to treatment failure, progression free survival, overall survival and duration of response (Phase I & II)

End point title	Time to treatment failure, progression free survival, overall survival and duration of response (Phase I & II)
-----------------	----------------------------------------------------------------------------------------------------------------

End point description:

Time to treatment failure (TTF) was defined as the time from first administration of study product until the date of the last administration of the product, irrespective of the reason for study treatment

discontinuation. Progression-free survival (PFS) was defined as the time from first administration of study product until the date of either disease progression or death (for whatever reason), whichever comes first. Overall survival (OS) was defined as the time from first administration of study product until death. Duration of response (DR) was defined as the time from the first objective response (OR) or SD assessment until the first assessment of PD. The value "9999" is a placeholder as the 95% confidence interval lower limit was below the limit of detection.

End point type	Secondary
End point timeframe:	
Up to Month 54	

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	GSK2302025A Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	24	22	40
Units: Months				
median (confidence interval 95%)				
TTF	2.3 (1.0 to 4.9)	2.3 (1.3 to 4.2)	3.0 (2.3 to 4.9)	4.6 (2.7 to 5.3)
PFS	2.7 (1.4 to 2.9)	2.7 (1.0 to 2.8)	2.8 (2.1 to 2.9)	2.8 (2.7 to 3.3)
OS	17.0 (8.1 to 9999)	11.5 (7.3 to 9999)	10.8 (8.4 to 25.5)	23.0 (15.5 to 9999)
DR	43.8 (19.0 to 48.6)	42.4 (23.7 to 45.9)	42.1 (40.1 to 46.0)	26.5 (22.8 to 28.0)

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of response for patients with CR, PR and SD or SD/PR status (Phase II)

End point title	Duration of response for patients with CR, PR and SD or SD/PR status (Phase II)
-----------------	---------------------------------------------------------------------------------

End point description:

Following negative results to the NCT00480025 study which assessed another study product from same technology platform. For this study, the main analysis of the dose-escalation Phase I segment was performed according to protocol when all patients enrolled in the Phase I segment had received the first 4 treatment doses and had completed Week 8. The main analysis of the Phase II segment was performed according to protocol when all patients had either completed the treatment until the end of Cycle 3 or had been withdrawn from the study treatment, with the exception of anti-CpG/anti-PD antibody responses and PRAME-specific cellular responses which were not yet performed. All samples that had been collected but not yet tested were not tested by default, except if a scientific rationale remained relevant.

End point type	Secondary
End point timeframe:	
Up to data lock point LPLV for Main analysis in Phase II	

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	GSK2302025A Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[15]	0 ^[16]	0 ^[17]	0 ^[18]
Units: Months				
median (confidence interval 95%)				
Months	(to)	(to)	(to)	(to)

Notes:

[15] - This analysis was not performed.

[16] - This analysis was not performed.

[17] - This analysis was not performed.

[18] - This analysis was not performed.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with stable disease (SD), progressive disease (PD), mixed response (MR) (Phase I & II)

End point title	Number of subjects with stable disease (SD), progressive disease (PD), mixed response (MR) (Phase I & II)
-----------------	-----------------------------------------------------------------------------------------------------------

End point description:

Tumor response was assessed by the RECIST criteria, where SD for target lesions refers to neither enough shrinkage to qualify for CR nor sufficient increase to qualify for PD taking as references the smallest sum LD since the treatment started. For non-targeted lesions it refers to persistence of one or more non-target lesions. Progressive disease is related to a clear increase of diameters of lesions taking as references the smallest diameters recorded since the treatment started OR the appearance of one or more new lesions OR both of these.

End point type	Secondary
----------------	-----------

End point timeframe:

At 30 days after the last treatment administration for each patient

End point values	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3	GSK2302025A Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	24	22	40
Units: Participants				
Complete response	0	0	0	0
Partial response	0	0	0	4
Stable disease	2	1	1	1
Stable Disease/Progressive disease	0	1	1	3
Progressive disease	9	18	15	31
Non Evaluable	2	1	0	1
Missing Best overall response	7	3	5	0
Disease control: Yes	2	2	2	8
Disease control: No	18	22	20	32

Statistical analyses

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From study start to Month 49.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.1
--------------------	------

Reporting groups

Reporting group title	GSK2302025A Cohort 1
-----------------------	----------------------

Reporting group description:

Subjects will receive investigational dose-level A (different from dose-levels B and C). Patients will receive a treatment consisting of 24 injections of the experimental GSK2302025A immunotherapeutic

Reporting group title	GSK2302025A Cohort 2
-----------------------	----------------------

Reporting group description:

Subjects will receive investigational dose-level B (different from dose-levels A and C). Patients will receive a treatment consisting of 24 injections of the experimental GSK2302025A immunotherapeutic

Reporting group title	GSK2302025A Cohort 3
-----------------------	----------------------

Reporting group description:

Subjects will receive investigational dose-level C (different from dose-levels A and B). Patients will receive a treatment consisting of 24 injections of the experimental GSK2302025A immunotherapeutic

Reporting group title	GSK2302025A Cohort 4
-----------------------	----------------------

Reporting group description:

In Phase 2 of the study subjects will receive the optimal investigational dose-level identified in Phase 1. Patients will receive a treatment consisting of 24 injections of the experimental GSK2302025A immunotherapeutic

Serious adverse events	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 20 (15.00%)	3 / 24 (12.50%)	2 / 22 (9.09%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Renal neoplasm			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Circulatory collapse			

subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Brain oedema			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Intestinal obstruction			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholestasis			

subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Skin ulcer			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Bursitis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			

subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Erysipelas			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected skin ulcer			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	GSK2302025A Cohort 4		
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 40 (12.50%)		
number of deaths (all causes)	2		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Renal neoplasm			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Circulatory collapse			

subjects affected / exposed	1 / 40 (2.50%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Brain oedema			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sciatica			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Intestinal obstruction			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholestasis			

subjects affected / exposed	1 / 40 (2.50%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Pneumothorax			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Skin ulcer			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Bursitis			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteoarthritis			

subjects affected / exposed	0 / 40 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Erysipelas			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infected skin ulcer			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Subcutaneous abscess			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	GSK2302025A Cohort 1	GSK2302025A Cohort 2	GSK2302025A Cohort 3
Total subjects affected by non-serious adverse events			
subjects affected / exposed	19 / 20 (95.00%)	21 / 24 (87.50%)	21 / 22 (95.45%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Uterine leiomyoma			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Arteriosclerosis moenckeberg-type			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0

Haemorrhage			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Hyperaemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
Hypertension			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	2 / 22 (9.09%)
occurrences (all)	1	0	3
Hypotension			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences (all)	1	0	1
Lymphoedema			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Lymphostasis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
Peripheral coldness			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Thrombophlebitis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Surgical and medical procedures			
Catheter placement			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Tooth extraction			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
General disorders and administration site conditions			
Administration site induration subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	1 / 22 (4.55%) 3
Administration site pain subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 24 (4.17%) 2	1 / 22 (4.55%) 2
Asthenia subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2	0 / 24 (0.00%) 0	6 / 22 (27.27%) 21
Axillary pain subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 24 (4.17%) 1	0 / 22 (0.00%) 0
Chest discomfort subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 6	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Chills subjects affected / exposed occurrences (all)	4 / 20 (20.00%) 10	1 / 24 (4.17%) 2	4 / 22 (18.18%) 14
Fatigue subjects affected / exposed occurrences (all)	4 / 20 (20.00%) 10	7 / 24 (29.17%) 36	6 / 22 (27.27%) 10
Feeling cold subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 2	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Feeling hot subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Gait disturbance subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Hyperplasia			

subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Hyperthermia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences (all)	1	0	1
Inflammation			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Influenza like illness			
subjects affected / exposed	4 / 20 (20.00%)	6 / 24 (25.00%)	7 / 22 (31.82%)
occurrences (all)	18	11	16
Injection site discomfort			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Injection site erythema			
subjects affected / exposed	3 / 20 (15.00%)	7 / 24 (29.17%)	7 / 22 (31.82%)
occurrences (all)	13	17	14
Injection site induration			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	4
Injection site inflammation			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	0	2	0
Injection site pain			
subjects affected / exposed	9 / 20 (45.00%)	10 / 24 (41.67%)	12 / 22 (54.55%)
occurrences (all)	39	32	51
Injection site oedema			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	2 / 22 (9.09%)
occurrences (all)	0	3	4
Injection site pruritus			
subjects affected / exposed	2 / 20 (10.00%)	2 / 24 (8.33%)	1 / 22 (4.55%)
occurrences (all)	2	2	8
Injection site reaction			
subjects affected / exposed	5 / 20 (25.00%)	4 / 24 (16.67%)	2 / 22 (9.09%)
occurrences (all)	6	8	5
Injection site swelling			

subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	2 / 22 (9.09%)
occurrences (all)	0	4	4
Malaise			
subjects affected / exposed	1 / 20 (5.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	2	1	0
Oedema			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	2 / 22 (9.09%)
occurrences (all)	0	0	3
Oedema peripheral			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	1 / 22 (4.55%)
occurrences (all)	0	1	1
Pain			
subjects affected / exposed	2 / 20 (10.00%)	0 / 24 (0.00%)	3 / 22 (13.64%)
occurrences (all)	2	0	4
Pyrexia			
subjects affected / exposed	6 / 20 (30.00%)	8 / 24 (33.33%)	5 / 22 (22.73%)
occurrences (all)	20	22	8
Swelling			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Xerosis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Metrorrhagia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Uterine haemorrhage			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			

Cough			
subjects affected / exposed	0 / 20 (0.00%)	2 / 24 (8.33%)	0 / 22 (0.00%)
occurrences (all)	0	6	0
Dyspnoea			
subjects affected / exposed	1 / 20 (5.00%)	2 / 24 (8.33%)	0 / 22 (0.00%)
occurrences (all)	2	2	0
Haemoptysis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Oropharyngeal pain			
subjects affected / exposed	1 / 20 (5.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	1	2	0
Respiratory disorder			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	0	2	0
Anxiety			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Confusional state			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
Depression			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
Dissociation			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Insomnia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	1 / 22 (4.55%)
occurrences (all)	0	1	1
Mood altered			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	1 / 22 (4.55%) 1
Investigations			
Antinuclear antibody increased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 24 (4.17%) 1	0 / 22 (0.00%) 0
Blood bilirubin increased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Blood glucose increased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Blood lactic acid increased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 24 (4.17%) 1	0 / 22 (0.00%) 0
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	1 / 22 (4.55%) 1
Blood urea increased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 24 (4.17%) 1	0 / 22 (0.00%) 0
Body temperature increased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 24 (4.17%) 1	0 / 22 (0.00%) 0
Cortisol decreased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Cortisol increased subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Creatinine renal clearance decreased			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 24 (4.17%) 1	0 / 22 (0.00%) 0
Eosinophil count increased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	1 / 22 (4.55%) 1
Haemoglobin decreased subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Liver function test subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Injury, poisoning and procedural complications Traumatic haematoma subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Cardiac disorders Nodal arrhythmia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 24 (4.17%) 1	0 / 22 (0.00%) 0
Palpitations subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Nervous system disorders Amnesia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	1 / 22 (4.55%) 2
Burning sensation subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Dizziness			

subjects affected / exposed	2 / 20 (10.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences (all)	2	0	1
Headache			
subjects affected / exposed	6 / 20 (30.00%)	5 / 24 (20.83%)	4 / 22 (18.18%)
occurrences (all)	12	43	9
Neuralgia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences (all)	1	0	1
Paraesthesia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Parosmia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Sensory loss			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Seizure			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 20 (0.00%)	3 / 24 (12.50%)	0 / 22 (0.00%)
occurrences (all)	0	3	0
Leukopenia			
subjects affected / exposed	1 / 20 (5.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	1	1	0

Lymph node pain subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Neutropenia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Ear and labyrinth disorders			
Ear haemorrhage subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	1 / 22 (4.55%) 1
Ear pain subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Hypoacusis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Tinnitus subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 24 (4.17%) 1	0 / 22 (0.00%) 0
Eye disorders			
Conjunctivitis allergic subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Eyelid oedema subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Gastrointestinal disorders			
Abdominal discomfort subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 24 (4.17%) 1	0 / 22 (0.00%) 0
Abdominal distension subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	1 / 22 (4.55%) 1
Abdominal pain			

subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	2 / 22 (9.09%)
occurrences (all)	1	0	4
Abdominal pain upper			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	2 / 22 (9.09%)
occurrences (all)	0	0	2
Constipation			
subjects affected / exposed	1 / 20 (5.00%)	2 / 24 (8.33%)	2 / 22 (9.09%)
occurrences (all)	1	2	2
Dental caries			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	1 / 20 (5.00%)	1 / 24 (4.17%)	1 / 22 (4.55%)
occurrences (all)	2	1	1
Dry mouth			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Dysphagia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	0	2	0
Flatulence			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal motility disorder			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	5 / 20 (25.00%)	4 / 24 (16.67%)	2 / 22 (9.09%)
occurrences (all)	5	8	2
Odynophagia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Oesophagitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Vomiting			

subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2	4 / 24 (16.67%) 8	0 / 22 (0.00%) 0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Alopecia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Dermatitis atopic			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	3 / 22 (13.64%)
occurrences (all)	0	0	4
Hyperhidrosis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
Intertrigo			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
Papule			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences (all)	1	0	2
Purpura senile			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	1 / 22 (4.55%)
occurrences (all)	0	1	1

Rash pruritic subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Skin lesion subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Skin irritation subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Vitiligo subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Renal and urinary disorders			
Albuminuria subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Hyperoxaluria subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Microalbuminuria subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	2 / 22 (9.09%) 4
Nocturia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Pollakiuria subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	1 / 22 (4.55%) 1
Proteinuria subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 24 (4.17%) 2	1 / 22 (4.55%) 2
Polyuria subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Renal colic			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Renal impairment subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Endocrine disorders Adrenal insufficiency subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	1 / 22 (4.55%) 1
Glucocorticoid deficiency subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	2 / 24 (8.33%) 24	1 / 22 (4.55%) 1
Back pain subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 2	0 / 24 (0.00%) 0	1 / 22 (4.55%) 1
Bone pain subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 5	1 / 24 (4.17%) 2	0 / 22 (0.00%) 0
Groin pain subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 24 (0.00%) 0	1 / 22 (4.55%) 1
Hypercreatinaemia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 24 (4.17%) 1	0 / 22 (0.00%) 0
Joint ankylosis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Joint swelling subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 24 (0.00%) 0	0 / 22 (0.00%) 0
Limb discomfort			

subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal chest pain			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Muscle spasms			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
Musculoskeletal pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	4 / 20 (20.00%)	2 / 24 (8.33%)	1 / 22 (4.55%)
occurrences (all)	5	5	1
Pain in extremity			
subjects affected / exposed	1 / 20 (5.00%)	2 / 24 (8.33%)	2 / 22 (9.09%)
occurrences (all)	1	13	3
Infections and infestations			
Bacteriuria			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Bronchitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Bronchitis viral			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Infection			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0

Influenza			
subjects affected / exposed	2 / 20 (10.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	3	0	0
Localised infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Periodontitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
Pharyngitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
Rash pustular			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	1 / 20 (5.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	1	1	0
Skin infection			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Tinea infection			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	1 / 22 (4.55%)
occurrences (all)	1	0	1
Urinary tract infection			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	0	3	0

Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Decreased appetite			
subjects affected / exposed	2 / 20 (10.00%)	2 / 24 (8.33%)	1 / 22 (4.55%)
occurrences (all)	3	8	1
Hypercholesterolaemia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Hyperuricaemia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Hypokalaemia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Hypoglycaemia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 24 (4.17%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 20 (0.00%)	0 / 24 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	GSK2302025A Cohort 4		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	37 / 40 (92.50%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Uterine leiomyoma			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Vascular disorders			
Arteriosclerosis moenckeberg-type			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Haemorrhage			

subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Hot flush			
subjects affected / exposed	2 / 40 (5.00%)		
occurrences (all)	2		
Hyperaemia			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Hypertension			
subjects affected / exposed	2 / 40 (5.00%)		
occurrences (all)	2		
Hypotension			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Lymphoedema			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Lymphostasis			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Peripheral coldness			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Thrombophlebitis			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Surgical and medical procedures			
Catheter placement			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Tooth extraction			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	2		

General disorders and administration site conditions			
Administration site induration			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Administration site pain			
subjects affected / exposed	2 / 40 (5.00%)		
occurrences (all)	4		
Asthenia			
subjects affected / exposed	13 / 40 (32.50%)		
occurrences (all)	32		
Axillary pain			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Chest discomfort			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Chills			
subjects affected / exposed	8 / 40 (20.00%)		
occurrences (all)	14		
Fatigue			
subjects affected / exposed	7 / 40 (17.50%)		
occurrences (all)	12		
Feeling cold			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Feeling hot			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Gait disturbance			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Hyperplasia			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Hyperthermia			

subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Inflammation			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Influenza like illness			
subjects affected / exposed	13 / 40 (32.50%)		
occurrences (all)	29		
Injection site discomfort			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Injection site erythema			
subjects affected / exposed	8 / 40 (20.00%)		
occurrences (all)	18		
Injection site induration			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Injection site inflammation			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Injection site pain			
subjects affected / exposed	24 / 40 (60.00%)		
occurrences (all)	90		
Injection site oedema			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Injection site pruritus			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Injection site reaction			
subjects affected / exposed	2 / 40 (5.00%)		
occurrences (all)	3		
Injection site swelling			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Malaise			

subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	3		
Oedema			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Oedema peripheral			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Pain			
subjects affected / exposed	8 / 40 (20.00%)		
occurrences (all)	9		
Pyrexia			
subjects affected / exposed	22 / 40 (55.00%)		
occurrences (all)	86		
Swelling			
subjects affected / exposed	2 / 40 (5.00%)		
occurrences (all)	4		
Xerosis			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Reproductive system and breast disorders			
Metrorrhagia			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Uterine haemorrhage			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	4 / 40 (10.00%)		
occurrences (all)	4		
Dyspnoea			

subjects affected / exposed	2 / 40 (5.00%)		
occurrences (all)	2		
Haemoptysis			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Oropharyngeal pain			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Respiratory disorder			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Anxiety			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Confusional state			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Depression			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Dissociation			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Insomnia			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Mood altered			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Investigations			
Antinuclear antibody increased			

subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Blood bilirubin increased			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Blood glucose increased			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Blood lactic acid increased			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Blood lactate dehydrogenase increased			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	2		
Blood urea increased			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Body temperature increased			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Cortisol decreased			
subjects affected / exposed	2 / 40 (5.00%)		
occurrences (all)	2		
Cortisol increased			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Creatinine renal clearance decreased			
subjects affected / exposed	4 / 40 (10.00%)		
occurrences (all)	4		
Eosinophil count increased			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Haemoglobin decreased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Liver function test</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 40 (0.00%)</p> <p>0</p> <p>0 / 40 (0.00%)</p> <p>0</p> <p>1 / 40 (2.50%)</p> <p>1</p>		
<p>Injury, poisoning and procedural complications</p> <p>Traumatic haematoma</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 40 (2.50%)</p> <p>1</p>		
<p>Cardiac disorders</p> <p>Nodal arrhythmia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Palpitations</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Sinus tachycardia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Tachycardia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 40 (0.00%)</p> <p>0</p> <p>1 / 40 (2.50%)</p> <p>1</p> <p>1 / 40 (2.50%)</p> <p>1</p> <p>1 / 40 (2.50%)</p> <p>1</p>		
<p>Nervous system disorders</p> <p>Amnesia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Burning sensation</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dizziness</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Headache</p>	<p>0 / 40 (0.00%)</p> <p>0</p> <p>1 / 40 (2.50%)</p> <p>1</p> <p>2 / 40 (5.00%)</p> <p>2</p>		

subjects affected / exposed	7 / 40 (17.50%)		
occurrences (all)	12		
Neuralgia			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Paraesthesia			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Parosmia			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Sciatica			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Sensory loss			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Seizure			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Somnolence			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Tremor			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Leukopenia			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Lymph node pain			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		

Neutropenia subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0		
Ear and labyrinth disorders			
Ear haemorrhage subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0		
Ear pain subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1		
Hypoacusis subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1		
Tinnitus subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0		
Vertigo subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0		
Eye disorders			
Conjunctivitis allergic subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1		
Eyelid oedema subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1		
Gastrointestinal disorders			
Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0		
Abdominal distension subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1		
Abdominal pain subjects affected / exposed occurrences (all)	3 / 40 (7.50%) 3		
Abdominal pain upper			

subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Constipation			
subjects affected / exposed	3 / 40 (7.50%)		
occurrences (all)	3		
Dental caries			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Diarrhoea			
subjects affected / exposed	5 / 40 (12.50%)		
occurrences (all)	7		
Dry mouth			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Dysphagia			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Flatulence			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Gastrointestinal motility disorder			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Nausea			
subjects affected / exposed	11 / 40 (27.50%)		
occurrences (all)	14		
Odynophagia			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Oesophagitis			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Vomiting			
subjects affected / exposed	5 / 40 (12.50%)		
occurrences (all)	5		
Skin and subcutaneous tissue disorders			

Acne			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Alopecia			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Dermatitis atopic			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	2		
Dry skin			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Erythema			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Hyperhidrosis			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Intertrigo			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Papule			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Pruritus			
subjects affected / exposed	2 / 40 (5.00%)		
occurrences (all)	2		
Purpura senile			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Rash			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Rash pruritic			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		

Skin lesion			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Skin irritation			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Vitiligo			
subjects affected / exposed	2 / 40 (5.00%)		
occurrences (all)	2		
Renal and urinary disorders			
Albuminuria			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Hyperoxaluria			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Microalbuminuria			
subjects affected / exposed	2 / 40 (5.00%)		
occurrences (all)	3		
Nocturia			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Pollakiuria			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Proteinuria			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Polyuria			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Renal colic			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Renal impairment			

subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1		
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Glucocorticoid deficiency			
subjects affected / exposed	2 / 40 (5.00%)		
occurrences (all)	2		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	6 / 40 (15.00%)		
occurrences (all)	7		
Back pain			
subjects affected / exposed	2 / 40 (5.00%)		
occurrences (all)	2		
Bone pain			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Groin pain			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Hypercreatinaemia			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Joint ankylosis			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Joint swelling			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Limb discomfort			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Musculoskeletal chest pain			

subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Muscle spasms			
subjects affected / exposed	4 / 40 (10.00%)		
occurrences (all)	6		
Musculoskeletal pain			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Myalgia			
subjects affected / exposed	5 / 40 (12.50%)		
occurrences (all)	5		
Pain in extremity			
subjects affected / exposed	8 / 40 (20.00%)		
occurrences (all)	9		
Infections and infestations			
Bacteriuria			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Bronchitis			
subjects affected / exposed	3 / 40 (7.50%)		
occurrences (all)	3		
Bronchitis viral			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Conjunctivitis			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Cystitis			
subjects affected / exposed	2 / 40 (5.00%)		
occurrences (all)	2		
Infection			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Influenza			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		

Localised infection			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Oral herpes			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Periodontitis			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Pharyngitis			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Rash pustular			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Rhinitis			
subjects affected / exposed	4 / 40 (10.00%)		
occurrences (all)	4		
Skin infection			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Tinea infection			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Urinary tract infection			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Metabolism and nutrition disorders			
Dehydration			

subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Decreased appetite			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	2		
Hypercholesterolaemia			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Hyperuricaemia			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		
Hypoglycaemia			
subjects affected / exposed	0 / 40 (0.00%)		
occurrences (all)	0		
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 40 (2.50%)		
occurrences (all)	1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

As a consequence of the decision to stop the study, not all data are available for a full final analysis as originally planned. Analyses are merely descriptive and the results are presented as an abridged study report.

Notes: